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Abstract
Background: According to available research, there have been no head-to-head studies comparing 
the effect of glucagon-like peptide 1 (GLP-1) agonists and sodium-glucose cotransporter 2 (SGLT-2) 
inhibitors on cardiovascular outcomes among patients with type 2 diabetes not reaching glycemic goal 
with metformin. 
Methods: Relevant studies were identified through electronic searches of PubMed and EMBASE pub-
lished up to January 15, 2020. Efficacy outcomes of interest included the composite of cardiovascular 
death, non-fatal myocardial infarction, or non-fatal stroke, its individual components, all-cause death, 
and hospitalization for heart failure (HF). Safety outcomes included all suggested side effects of both 
agents previously reported. 
Results: Eleven studies, including 94,727 patients were used for the analysis. The risk of composite 
end point was significantly lower in both groups compared to the control group (hazard ratio [HR] 0.88, 
95% confidence interval [CI] 0.85–0.92, p < 0.001). The risk of hospitalization for HF was significantly 
lower in both groups but the magnitude of the effect was more pronounced in the SGLT-2 inhibitors 
group (HR 0.68, 95% CI 0.60–0.76, p < 0.001) than the GLP-1 agonists group (HR 0.92, 95% CI 
0.84–0.99, p = 0.03). Patients treated with GLP-1 agonists discontinued trial medications more fre-
quently compared to conventionally treated patients because of serious side effects.
Conclusions: Both GLP-1 agonists and SGLT-2 inhibitors showed comparable cardiovascular out-
comes in patients with type 2 diabetes. However, the SGLT-2 inhibitors were associated with more pro-
nounced reduction of hospitalization for HF and lower risk of treatment discontinuation than GLP-1 
agonists. (Cardiol J)
Key words: diabetes mellitus, sodium-glucose transporter 2 inhibitors, glucagon-like 
peptide 1 receptor, cardiovascular disease
Introduction
Use of appropriate antidiabetic drugs has 
become an important issue in diabetic patients 
with atherosclerotic cardiovascular disease 
(CVD) and those with multiple risk factors [1, 2]. 
Although metformin is generally recommended 
and widely used as a first-line therapy due to its 
cardioprotective effects, selection of a subse-
quent antidiabetic agent among type 2 diabetic 
patients who failed to reach their glycemic goal 
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Several classes of antidiabetic agents have been 
effective in glycemic control when added to met-
formin and these include the incretin-based dipep-
tidyl peptidase 4 (DPP-4) inhibitors, glucagon--like 
peptide 1 (GLP-1) agonists [5], and sodium-glucose 
cotransporter 2 (SGLT-2) inhibitors. Current guide-
lines recommend addition of either SGLT-2 inhibi-
tors or GLP-1 agonists in type 2 diabetes patients 
who failed to achieve their glycemic goal with met-
formin monotherapy or even as a first-line therapy 
for patients with atherosclerotic CVD [4, 6, 7].
Contrary to recent trials of DPP-4 inhibitors 
that did not show benefits or harms, several GLP-1 
agonists and SGLT-2 inhibitors were effective in 
terms of cardiovascular outcomes [8–17]. Under-
standing cardiovascular outcomes of second-line 
antidiabetic agents in high-risk diabetic patients 
could help physicians to select treatment strategy 
after failure of metformin-based antidiabetic man-
agement. However, there were no head-to-head 
studies comparing the efficacy of both classes of 
antidiabetic agents. The purpose of this study was 
to investigate the effectiveness of GLP-1 agonists 
and SGLT-2 inhibitors and their safety profiles.
Methods
Data sources
Relevant studies were identified through elec-
tronic searches of PubMed and EMBASE published 
up to January 15, 2020. Medical subject headings 
and keyword searches included the terms ‘empagli-
flozin’, ‘canagliflozin’, ‘dapagliflozin’, ‘ertugliflozin’, 
‘lixisenatide’, ‘exenatide’, ‘liraglutide’, ‘semaglu-
tide’, ‘albiglutide’, ‘dulaglutide’, ‘heart infarction’, 
‘myocardial infarction’, ‘cerebrovascular accident’, 
‘stroke’, ‘death’, ‘major adverse cardiac event’, 
‘mace’, ‘major adverse cardiovascular event’, ‘heart 
failure’, ‘controlled study’, ‘random’, and ‘placebo’. 
Reference lists of selected articles were system-
atically reviewed for other potentially relevant 
citations. No language restriction was enforced.
Study selection
Two investigators (S.-H.L. and J.-S.J.) in-
dependently conducted the literature search, 
data extraction, and quality assessment by using 
a standardized approach. Selected publications 
were reviewed by the same investigators to assess 
if studies met the inclusion criteria: (1) randomized 
allocation; (2) all participants with type 2 diabetes 
mellitus; (3) comparison of GLP-1 agonist or SGLT-2 
inhibitor with a control group; (4) follow-up of more 
than 1 year.
Data extraction
Two reviewers (Y.-M.L. and J.-S.J.) extracted 
relevant information from the articles including 
study treatment, study period, patient character-
istics (mean age, gender distribution, duration of 
diabetes, history of atherosclerotic CVD and heart 
failure [HF]), sample size, estimated glomerular 
filtration rates. Reviewers were not blinded to the 
articles, publication sites, and affiliation of authors.
End points
Efficacy end points of this study were the com-
posite of cardiovascular death, non-fatal myocardial 
infarction (MI), or non-fatal stroke, its individual 
components, all-cause death, and hospitalization 
for HF. Safety end points of interest included pan-
creatitis, pancreatic cancer, retinopathy, genital 
and urinary tract infection, diabetic ketoacidosis, 
lower limb amputations, fractures, acute kidney 
injury, any malignancy, severe hypoglycemia, and 
discontinuation of study medications. 
Data synthesis and analysis
Hazard ratios (HRs) were  pooled with 95% 
confidence intervals (CIs) for the effect of ran-
domizing treatment allocation on the outcomes 
across trials and the adjusted risk estimates were 
pooled after logarithmic transformation according 
to fixed-effects models with the generic inverse 
variance method. For safety outcomes, random-
-effects models producing across-study summary 
risk ratios (RRs) with 95% CIs were used. All 
p values were 2-tailed, with statistical significance 
set at 0.05. Included studies were well performed 
and the Cochrane tool for the assessment of risk 
bias in randomized clinical trials revealed low risk 
of bias in all studies [18]. Statistical heterogeneity 
between trials was assessed with I2 statistic, which 
is derived from the Cochran’s Q and the degree of 
freedom [100 × (Q – df)/Q]] [19]. I2 values lesser 
than 25%, greater than 25%, 50%, and 75% were 
considered as evidence of no, low, moderate, and 
severe statistical heterogeneity, respectively. If 
significant heterogeneity was noted across the 
studies, we then performed sensitivity analyses, 
serially excluding studies to determine the source 
of heterogeneity. Additionally, sensitivity analysis 
based on the different backbone across GLP-1 
agonist studies were conducted to examine the 
heterogeneity between exendin-4 analogues and 
human GLP-1 analogues. Publication bias was 
examined by visual inspection of constructed fun-
nel plots. All statistical analyses were performed 
using the Review Manager version 5.2 (The Nordic 
2 www.cardiologyjournal.org
Cardiology Journal 20XX, Vol. XX, No. X
Cochrane Center, Copenhagen, Denmark). Meta-
analysis was performed according the statement of 
Preferred Reporting Items for Systematic reviews 
and meta-analysis [20].
Results
The search strategy identified 309 potential 
articles, of which 32 were read in full text and 11 
clinical studies were included into the final analysis. 
Among them, 7 studies were phase 3, double-blind, 
placebo-controlled trials comparing GLP-1 agonists 
and standard treatment [9–11, 13, 21–23], while 
4 trials were phase 3, double-blind, placebo-con-
trolled trials comparing SGLT-2 inhibitors and 
control group [12, 17, 24, 25]. Table 1 summarizes 
characteristics of the included studies. Of the 94,727 
patients, 27,977 patients received GLP-1 agonists, 
21,266 patients received SGLT-2 inhibitors and 45,484 
patients were managed with conventional treatment. 
To compare different studies, regimen of study treat-
ment, duration of diabetes, glycated hemoglobin level, 
proportion of patients with atherosclerotic CVD and 
HF, and glomerular filtration rates were extracted 
(Table 1). Of the 7 GLP-1 agonists studies, only one 
of the latest studies [23] used oral regimen, instead 
of subcutaneous injection. Human GLP-1 analogues 
were used in 5 GLP-1 agonist studies [10, 11, 21–23] 
while exendin-4 analogues were used in 2 studies [9, 
13]. Primary end point of the included studies was 
composite of cardiovascular mortality, MI, or non-fatal 
stroke except for one study [24] reporting composite 
of renal outcomes and mortality.
Efficacy outcomes
Composite of cardiovascular death,  
non-fatal MI, or non-fatal stroke
Eleven studies including 94,727 patients were 
used for the analysis of composite end point. The 
risk for the composite end point of cardiovascular 
death, non-fatal MI, or non-fatal stroke was sig-
nificantly lower in both GLP-1 agonists group and 
SGLT-2 inhibitors group compared to the control 
group (HR 0.88, 95% CI 0.85–0.92, p < 0.001, Fig. 1). 
There was evidence of low statistical heterogene-
ity among the included studies (heterogeneity 
c2 = 13.13, I2 = 24%, p = 0.22).
Mortality, non-fatal MI, non-fatal stroke 
Pooled effects of cardiovascular mortality 
showed significantly lower rates in the GLP-1 
agonists and SGLT-2 inhibitors group compared 
to conventional treatment (HR 0.86, 95% CI 
0.81–0.92, p < 0.001, Fig. 2A). Low statistical 
heterogeneity was found among the included 
studies (heterogeneity c2 = 18.14, I2 = 45%, 
p = 0.05). All-cause death was also significantly 
lower in patients treated with both GLP-1 agonists 
and SGLT-2 inhibitors compared with the control 
group (HR 0.87, 95% CI 0.83– 0.91, p < 0.001). 
Both GLP-1 agonists and SGLT-2 inhibitors were 
associated with significantly lower rates of non-
fatal MI (HR 0.90, 95% CI 0.85–0.96, p < 0.001, 
Fig. 2B). Risk of non-fatal stroke was significantly 
lower with the use of GLP-1 agonists (HR 0.91, 
95% CI 0.83–0.99, p = 0.02) but not with the 
SGLT-2 inhibitors (HR 1.02, 95% CI 0.89–1.16, 
p = 0.81, Fig. 2C).
Hospitalization for heart failure
There was a substantial disparity between 
GLP-1 agonists and SGLT-2 inhibitors in the risk 
of hospitalization for HF. The risk of hospitaliza-
tion for HF was significantly lower in both GLP-1 
agonists group and SGLT-2 inhibitors group as 
compared to the control group (HR 0.83, 95% CI 
0.78–0.89, p < 0.001, Fig. 3), but the magnitude 
of effect was more pronounced in the SGLT-2 
inhibitors group (HR 0.68, 95% CI 0.60–0.76, 
p < 0.001) compared with the GLP-1 agonists group 
(HR 0.92, 95% CI 0.84–0.99, p = 0.03). There was 
no evidence of statistical heterogeneity among the 
included studies (GLP-1 agonists; heterogeneity 
c2 = 2.00, I2 = 0%, p = 0.92, SGLT-2 inhibitors; 
heterogeneity c2 = 1.32, I2 = 0%, p = 0.72).
Safety outcomes
In the analysis of safety outcomes, use of 
GLP-1 agonists was associated with a significantly 
increased risk of gastrointestinal events (RR 1.47, 
95% CI 1.06–2.02, p = 0.02), but did not influence 
the rates of pancreatitis (RR 0.72, 95% CI 0.37– 
–1.43, p = 0.35), pancreatic cancer (RR 1.17, 95% 
CI 0.74–1.85, p = 0.51) and retinopathy (RR 1.07, 
95% CI 0.88–1.29, p = 0.50) (Suppl. Fig. S1). 
Patients treated with SGLT-2 inhibitors showed 
a significantly increased risk of genital infection 
compared with the patients on conventional treat-
ment (RR 4.50, 95% CI 3.32–6.10, p < 0.001), but 
showed a similar risk of urinary tract infection (RR 
1.03, 95% CI 0.96–1.10, p = 0.38). Use of SGLT-2 
inhibitors tended to increase the risk of amputation 
(RR 1.31, 95% CI 1.00–1.70, p = 0.05), but the ex-
clusion of studies with canagliflozin demonstrated 
a similar risk of amputation between the canagli-
flozin and the conventional treatment group (RR 
1.08, 95% CI 0.90–1.28, p = 0.41) (Suppl. Fig. S2). 
The SGLT-2 inhibitors decreased the risk of acute 
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kidney injury compared with the conventional 
treatment (RR 0.75, 95% CI 0.62–0.89, p = 0.001).
Patients treated with GLP-1 agonists discon-
tinued trial medication more frequently compared 
to conventionally treated patients because of 
serious side effects (RR 1.50, 95% CI 1.24–1.81, 
p < 0.001, Fig. 4), but SGLT-2 inhibitors did not 
increase the rates of withdrawal (RR 1.10, 95% CI 
0.86–1.41, p = 0.44, Fig. 4).
Sensitivity analysis of different  
GLP-1 agonist studies
Stratified analysis according to the different 
GLP-1 agonists demonstrated  significantly lower 
rates of the composite end point of cardiovascular 
death, non-fatal MI, or non-fatal stroke compared 
to the control group in the studies of human GLP-1 
analogues (HR 0.84, 95% CI 0.79–0.90, p < 0.001), 
but not in studies using exendin-4 analogues (HR 
0.95, 95% CI 0.88–1.02, p = 0.16, Suppl. Fig. S3). 
Human GLP-1 analogue was associated with signifi-
cantly lower rates of non-fatal MI (HR 0.85, 95% CI 
0.77–0.94, p = 0.001) and non-fatal stroke (HR 0.80, 
95% CI 0.70–0.91, p < 0.001) than conventional 
regimen, whereas no significant differences were 
found in exendin-4 analogues group. Moreover, the 
risk of hospitalization for HF was significantly lower 
in the human GLP-1 analogues group as compared 
to the control group (HR 0.90, 95% CI 0.81–1.00, 
p = 0.005), but not in the exendin-4 analogues group 
(HR 0.94, 95% CI 0.82–1.07, p = 0.35).
Publication bias
Assessment of publication bias using RR of 
composite end point of cardiovascular death, non-
-fatal MI, or non-fatal stroke of the included studies 
showed a symmetric funnel plot with little evidence 
of publication bias.
Discussion
In this systematic review and meta-analysis of 
the 11 trials enrolling 94,727 patients with type 2 
diabetes, both GLP-1 agonists and SGLT-2 inhibi-
tors showed comparable efficacy in the reduction 
of composite end point of cardiovascular death, 
non-fatal MI, or non-fatal stroke as compared with 
the conventional antidiabetic treatment. There 
was also a comparably significant reduction in the 
respective risk of all-cause death, cardiovascular 
death and non-fatal MI in both groups. Also found 
was significantly lower risk of hospitalization for 
HF in both classes of experimental medications, 
especially more pronounced effect with SGLT-2 
inhibitors than GLP-1 agonists. Regarding safety 
outcomes, it was found that the GLP-1 agonists did 
not increase risk of pancreatitis, pancreatic cancer, 
or retinopathy. The SGLT-2 inhibitors showed 
a tendency toward increased risk of genital infection, 
but did not increase urinary tract infection compared 
with control group. Risk of non-fatal stroke was 
significantly lower with the use of GLP-1 agonists, 
but not with the use of SGLT-2 inhibitors. However, 
discontinuation of trial medication due to serious 
side effects was more frequently observed in pa-
tients receiving GLP-1 agonists treatment.
There have been no randomized clinical trials 
that directly compared the efficacy of GLP-1 ago-
nists and SGLT-2 inhibitors to improve cardiovas-
cular outcomes. Despite limitations of observation-
Figure 1. Hazard ratios for composite of cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke 
stratified by classes of anti-diabetic agent; CI — confidence interval.
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al studies, the CVD-REAL study demonstrated that 
use of SGLT-2 inhibitors lowered all-cause mor-
tality compared with other medications [26, 27]. 
In the EMPA-REG OUTCOME (Empagliflozin, 
Cardiovascular Outcomes, and Mortality in Type 2 
Diabetes) trial, which is a randomized, double-
-blind, placebo-controlled trial of 7,020 patients 
with type 2 diabetes, composite risk of MI, stroke, 
and cardiovascular death was significantly reduced 
with empagliflozin (HR 0.86, 95% CI 0.74–0.99) 
over a median follow-up of 3.1 years [17]. Car-
diovascular death (HR 0.62, 95% CI 0.49–0.77) 
Figure 2. Hazard ratios stratified by classes of anti-diabetic agent; A. Cardiovascular mortality; B. Non-fatal myocardial 
infarction; C. Non-fatal stroke; CI — confidence interval.
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Figure 3. Hazard ratios for hospitalization for heart failure stratified by classes of anti-diabetic agent; CI — confidence 
interval.
and all-cause death were reduced in a similar 
magnitude (HR 0.68, 95% CI 0.57–0.82) and there 
was also significant reduction in hospitalization 
for HF in the empagliflozin group (HR 0.65, 95% 
CI 0.50–0.85). However, a reduction in hospi-
talizations for HF and cardiovascular death in the 
empagliflozin group was observed consistently 
across patients who have HF or did not have HF 
at baseline [28].
The mechanism of beneficial effects for HF 
of SGLT-2 inhibitors has not been definitely de-
fined [29]. Recent studies of SGLT-2 inhibitors for 
prevention of cardiovascular and renal outcomes 
suggest that the renoprotective effects related with 
the natriuresis comprise a part of the reasons for 
the improvement in hospitalization for HF [30, 31]. 
The natriuresis induced by SGLT-2 inhibition is 
a stimulating factor for tubuloglomerular feedback, 
which, in turn causes afferent renal arteriolar vaso-
constriction. After the vasoconstriction of afferent 
arterioles of the kidney, resultant intraglomerular 
pressure reduction is caused and reduced intraglo-
merular pressure provides a renoprotective effect 
[32]. Furthermore, renoprotective effects and 
Figure 4. Hazard ratios for adverse events leading to discontinuation of study medication stratified by classes of anti-
diabetic agent; CI — confidence interval.
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natriuresis are especially beneficial in patients with 
impaired renal function at baseline who have sub-
stantial risk for hospitalization for HF [29]. A 32% 
reduction in the risk of hospitalization for HF and 
a 25% reduction in the rates of acute kidney injury 
in the present study might explain the reduced risk 
of cardiovascular death. Ongoing trials are assess-
ing cardioprotective effects of SGLT-2 inhibitors on 
hospitalization for HF in non-diabetic patients with 
HF as well as diabetic patients with HF [33].
In the present study, the SGLT-2 inhibitors 
were relatively well tolerated with lower incidence 
of serious adverse events compared with the GLP-1 
agonists that were associated with higher risk of 
adverse events leading to withdrawal of the study 
drug. As previously reported [34], gastrointestinal 
side effects were reported as the main side effect 
by GLP-1 agonists leading to participant withdrawal 
of study drug in our analysis. We think that SGLT-2 
inhibitors have an advantage over GLP-1 agonists 
in terms of lower rates of treatment discontinuation 
and this might help physicians to make a better 
treatment plan for diabetic patients who have failed 
to achieve their glycemic target with metformin 
monotherapy. 
Two studies with exendin-4 analogues (ex-
enatide and lixisenatide) did not reveal superior-
ity over control regimen with respect to clinical 
outcomes [9, 13]. In our analysis, human GLP-1 
analogues showed a greater effect on the composite 
end point of cardiovascular death, non-fatal MI, 
or non-fatal stroke compared to the control group 
but exendin-4 analogues did not. Differences in 
structure of GLP-1 agonists and subsequent dif-
ferent immunogenicity might be responsible for 
the better clinical outcomes in studies using hu-
man GLP-1 analogues than exendin-4 analogues 
[35]. Further studies are needed to elucidate how 
different molecular structure could affect diverse 
cardiovascular outcomes [36].
Limitations of the study
There are several limitations in this study. 
First, aggregated study-level data for meta-analysis 
was used instead of patient-level data. Therefore, 
a further subgroup-level study and quantified cu-
mulative follow-up time for end point events and 
safety events could not be investigated. Second, 
all of the trial did not use exactly the same defini-
tion of events, inclusion and exclusion criteria. 
But most of the definitions of events are very 
similar to each other, there would not have been 
a significant difference in event discrimination and 
there was no significant statistical heterogeneity 
among the included studies for analyses. Third, 
most of the included studies showed median follow-
-up duration shorter than 4 years. Because risk fac-
tors for CVD is chronic diseases and some of side 
effects may occur later over time, there is a strong 
need for long-term follow-up. Fourth, this study 
lacks evidence for diabetic patients with low cardio-
vascular risk. Most of the included study targeted 
diabetic patients with established CVD or high-risk 
patients. Until now there is no definite treatment op-
tion about second-line antidiabetic agents improving 
cardiovascular outcomes for diabetic patients with 
low cardiovascular risk. Finally, this study is not 
a direct head-to-head study but compared SGLT-2 
inhibitors with GLP-1 agonists indirectly. Despite 
being an indirectly comparative study, consistent 
results of efficacy and safety outcomes were found 
across most of the included studies. Furthermore, 
the results of this study add to a growing body of 
evidence in the literature aggregating individual 
studies that compared SGLT-2 inhibitors and GLP-1 
agonist as second-line antidiabetic agents with 
conventional therapy.
Conclusions
Both GLP-1 agonists and SGLT-2 inhibitors 
showed comparable efficacy in reducing composite 
cardiovascular outcomes, mortality, and MI as com-
pared to conventional antidiabetic medications in 
patients with type 2 diabetes. Safety analyses of the 
included studies revealed increased risk of genital 
infections by SGLT-2 inhibitors, and use of GLP-1 
agonists were associated with a higher risk of 
adverse events leading to medication withdrawal. 
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